ATOSSA THERAPEUTICS INC. - COMMON STOCK

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 4 2024 11:59:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

05 4 2024 09:58:53 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 4 2024 11:38:29 提供 NetDania Notify

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

01 4 2024 12:27:21 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

28 3 2024 10:08:00 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

26 3 2024 09:45:03 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

25 3 2024 10:40:51 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

20 3 2024 09:45:01 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

19 3 2024 10:49:14 提供 NetDania Notify

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders

09 1 2024 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

04 12 2023 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

20 11 2023 08:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 11 2023 09:00:00 提供 Nasdaq GlobeNewswire